A Patient With EGFR-Mutated Lung Cancer Progressing on Erlotinib: Evaluating for a T790M Mutation With Limited Tissue

Due to the high rate ofEGFR T790M mutations seen in NSCLC patients, the thoracic tumor board recommends genomic testing for this alteration; read our case of a 69-year-old woman with metastatic disease.

Source: CancerNetwork - October 17, 2018 Category: Cancer & Oncology Authors: Emily Wynja, MSIV, Jenna Hove, BSN, Steven F. Powell, MD Source Type: news